ABT 560

Drug Profile

ABT 560

Alternative Names: ABT-560; ABT-PR2

Latest Information Update: 05 Feb 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NeuroSearch
  • Developer Abbott Laboratories
  • Class
  • Mechanism of Action Alpha4beta2 nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cognition disorders

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
  • 21 Oct 2011 ABT 560 is still in Phase-I trials for Cognition disorders in USA
  • 28 Sep 2011 ABT 560 is available for licensing as of 28 Sep 2011. http://neurosearch.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top